Our Team


President & Founder

Lyle Arnold, Ph.D. is the founder, CEO, and President of AEGEA. Dr. Arnold is an experienced biotechnology executive, entrepreneur, and developer of innovative technologies covering therapeutics, molecular diagnostics, and genomics. Beyond AEGEA, Dr. Arnold also serves as the Chief Scientific Officer of Biocept, Inc., a clinical lab testing company focused on circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) analysis. Dr. Arnold has served on the board of directors of numerous companies, including Asuragen, as well as, non-profit organizations, and currently serves as chairman of AEGEA. 

He has also held senior scientific and management positions at Molecular Biosystems (co-founder), Genta, Synteni, Incyte Genomics, Oasis Biosciences (co-founder), and Gen-Probe (now Hologic). In addition, Dr. Arnold was a faculty member in the UCSD School of Medicine and a member of the UCSD Cancer Center. Dr. Arnold is an inventor or co-inventor on 50 issued U.S. patents and more than 160 issued and pending patents worldwide. He is a joint inventor, together with Dr. Norm Nelson, of the chemiluminescent Hybridization Protection Assay (HPA) and associated technologies core to Hologic assays that generate more than $500M in product revenue annually. Dr. Arnold is also the inventor of the patented Switch-Blocker technology that is jointly assigned to AEGEA and Biocept. This technology is highly sensitive and specific for detecting extremely rare genetic events. Biocept uses this technology for clinical assay that interrogate ctDNA for cancer associated mutations, to aid physicians in making treatment decisions for their patients. In addition, Dr. Arnold has authored more than 50 scientific publications.

Dr. Arnold received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego.

VP, Operations and Development

Norm Nelson, PhD is VP, Operations and Development. Dr. Nelson was associated with Gen-Probe for 27 years and held positions of increasing responsibility culminating in a position of Senior Director. Dr. Nelson has extensive experience in the development of FDA-regulated Molecular Diagnostics. He is also an expert in Next Generation Sequencing and has deep experience in leading/managing NGS platform development programs. He also has a proven track record in innovation and core technology development, as well as the associated reduction to practice and implementation to enable new molecular diagnostic assays. As an inventor or co-inventor on 41 issued U.S. patents, and more than 160 issued and pending patents world-wide, he played a key role in the commercialization of multiple technologies, many of which are core to Gen-Probe products that generate >$500MM in annual revenue. He also has broad expertise and experience in intellectual property protection, including serving as an expert witness on patent cases. Dr. Nelson received his B.S. degree in Chemistry from the California Institute of Technology, and his Ph.D. degree in Chemistry/Biochemistry from the University of California at San Diego.


Acting Sr. VP, Business Development 

Michael Dunn is Sr. VP Business Development. Mr. Dunn has 30 years of experience in the pharmaceutical and biotech industries.  Mr. Dunn also currently serves as President, Chief Operating Officer and Director of CalciMedica, Inc. Previously, Mr. Dunn was Sr. VP, Corporate Development at Biocept. He also served as Vice President and Chief Business Officer of Monogram BioSciences, a biotech laboratory specializing in infectious disease and cancer testing, which was acquired by LabCorp in 2009.   Mr. Dunn served as Vice President and Chief Business Officer of Aclara BioSciences, a company specializing in microfluidic chips and oncology testing through its merger with Virologic, Inc., as well as Vice President and Chief Business Officer at ActivX BioSciences, a biopharmaceutical company that utilizes proteomics to discover and develop small molecule drugs for major unmet medical needs.  Additionally, Mr. Dunn served as Vice President of Business Development at Aurora BioSciences, a company that developed and commercialized proprietary drug discovery systems, services and technologies through  its acquisition by Vertex Pharmaceuticals.  Mr. Dunn began his biotech career with various project management and business development roles at the Salk Institute Biotechnology Industrial Associates Studies (SIBIA) and it successor SIBIA Neurosciences, which he helped to take public, culminating there as VP of Business Development.  SIBIA was acquired by Merck in 1999.  Mr. Dunn holds a B.A. in Biology from the University of Chicago and a MBA in Finance from the University of San Diego.